AJOVista LLC Acquires Shares of 509 Eli Lilly and Company (NYSE:LLY)

AJOVista LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 509 shares of the company’s stock, valued at approximately $297,000.

Other institutional investors have also recently made changes to their positions in the company. Nadler Financial Group Inc. grew its stake in shares of Eli Lilly and Company by 6.8% during the 3rd quarter. Nadler Financial Group Inc. now owns 2,362 shares of the company’s stock worth $1,269,000 after purchasing an additional 150 shares during the period. Center for Financial Planning Inc. increased its holdings in Eli Lilly and Company by 26.5% in the third quarter. Center for Financial Planning Inc. now owns 506 shares of the company’s stock valued at $272,000 after buying an additional 106 shares in the last quarter. Stonegate Investment Group LLC raised its position in shares of Eli Lilly and Company by 0.8% in the third quarter. Stonegate Investment Group LLC now owns 67,681 shares of the company’s stock worth $36,354,000 after acquiring an additional 537 shares during the period. Affinity Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 1.8% during the 3rd quarter. Affinity Wealth Management LLC now owns 12,916 shares of the company’s stock worth $6,937,000 after acquiring an additional 228 shares in the last quarter. Finally, Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $35,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.8 %

NYSE LLY traded down $20.94 during trading hours on Friday, hitting $734.97. 4,595,138 shares of the company were exchanged, compared to its average volume of 2,629,045. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a PEG ratio of 1.46 and a beta of 0.37. The company has a 50 day moving average of $761.06 and a two-hundred day moving average of $671.38. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the previous year, the business posted $1.62 EPS. The firm’s revenue was up 26.0% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Analysts Set New Price Targets

LLY has been the subject of several recent analyst reports. Truist Financial boosted their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Finally, Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.